Editas Medicine (NASDAQ:EDIT) announced first-quarter 2018 results on Thursday after the market closed, detailing expanded partnerships, progress for its important LCA10 drug candidate, and a number of other intriguing updates for the broader business.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,